You’ve just been diagnosed with stage III pancreatic cancer, you are not alone. The American Cancer Society estimates that in the United States in 2019, approximately 57,000 people will be diagnosed with pancreatic cancer1. Dealing with this disease can be overwhelming. It is important to talk with your family and healthcare team to educate yourself on all available options.
DIRECT by AngioDynamics is a comprehensive clinical study that will evaluate the effects of Irreversible Electroporation (IRE) ablation technology on people suffering with stage III pancreatic cancer. The study is composed of a real-world, controlled Registry and an additional Randomized Control Trial (RCT). This innovative study is designed to provide the most complete form of evidence available to patients, clinicians, payors and regulators.
If you would like to learn more about the DIRECT study, please call our DIRECT study support line at +1 (800) 584-7608.
The DIRECT study, which was initiated by AngioDynamics, is led by Co-Principal Investigators – Govindarajan Narayanan, MD, Chief of Interventional Oncology at Miami Cancer Institute and Robert C.G. Martin, MD, PhD, Surgical Oncology at the University of Louisville. Together, with their extensive medical experience and passion towards clinical studies and research, we hope to drive the DIRECT study forward.